home / stock / rptx / rptx news

RPTX News and Press, Repare Therapeutics Inc. From 11/02/21

Stock Information
Company Name: Repare Therapeutics Inc.
Stock Symbol: RPTX
Market: NASDAQ
Website: reparerx.com
Menu
RPTX RPTX Quote RPTX Short RPTX News RPTX Articles RPTX Message Board
Get RPTX Alerts

News, Short Squeeze, Breakout and More Instantly...
RPTX - Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the closing on November 1, 2021 of its upsized underwritten public offering of 4,...
RPTX - Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares

Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of an upsized underwritten public offering of 4,000,000 of its common...

RPTX - Repare Therapeutics Announces Proposed Public Offering of Common Shares

Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the commencement of a proposed underwritten public offering of $75.0 million of i...

RPTX - Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright 2 nd Annual Pre...
RPTX - Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics' SNIPRx platform for molecular selection of tumors for therapy with RP-3500 Favorable and differentiated safety profile, along with promising and distinct early activity, offer clear directio...

RPTX - Hot Stocks: F, TTM deal rumors; TTWO release; RPTX clarifies data; OMER downgrade; IMOS misses revenue

Deal speculation involving Ford (NYSE:F) and Tata Motors (NYSE:TTM) sparked buying interest in Friday's midday trading. The companies are reportedly working on a deal for Ford's India operations. Take-Two Interactive (NASDAQ:TTWO) was another high-profile name garnering attention in intraday ...

RPTX - Repare Therapeutics Issues Statement Regarding Inadvertent Issuance of Phase 1/2 TRESR RP-3500 Clinical Trial Abstract by the AACR-NCI-EORTC Virtual International Conference

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today issued the following statement concerning the inadvertent issuance of an abstract by the AACR-NCI-EORTC Virtual International Confe...
RPTX - Repare Therapeutics to Present Initial Data from the Phase 1/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Clinical Trial Selected for Oral Presentation on Friday, October 8 at 3:15 p.m. ET Preclinical Data Poster Presentation for RP-3500 Alone and in Combination with PARP Inhibitors Company Virtual Webcast Event on Friday, October 8 at 5:00 p.m. ET Repare Therape...

RPTX - Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman

Former CEO of Five Prime Therapeutics brings over 25 years of leadership and commercial experience in pharma, biotech and molecular Dx Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology...

RPTX - Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that membe...
Previous 10 Next 10